Vertex to Acquire Crinetics for $85/Share, Secures $4.5B Bridge Loan
VRTX sits 46% above its 52-week low of $362.5.
Summary
Vertex Pharmaceuticals announced it will acquire Crinetics Pharmaceuticals for $85 per share in cash. This news provides specific per-share pricing and financing details for the $10 billion acquisition that was initially disclosed in a Dow Jones Newswires report and an 8-K filing yesterday. Vertex has secured a $4.5 billion unsecured 364-day bridge loan to backstop the purchase price. The deal is expected to close in the third quarter of 2026, pending regulatory and shareholder approvals. Traders will be watching for details on the permanent financing plan for the remaining acquisition cost.
At the time of this announcement, VRTX was trading at $528.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $134.4B. The 52-week trading range was $362.50 to $529.99. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.